666 related articles for article (PubMed ID: 19581668)
21. The detection of colorectal cancer at an asymptomatic stage by screening is useful.
Komuta K; Furui J; Haraguchi M; Kanematsu T
Hepatogastroenterology; 2000; 47(34):1011-4. PubMed ID: 11020866
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
[TBL] [Abstract][Full Text] [Related]
23. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study.
Rozen P; Knaani J; Samuel Z
Cancer; 2000 Jul; 89(1):46-52. PubMed ID: 10896999
[TBL] [Abstract][Full Text] [Related]
24. Fecal occult blood testing for colorectal cancer screening: use the finger.
Burke CA; Tadikonda L; Machicao V
Am J Gastroenterol; 2001 Nov; 96(11):3175-7. PubMed ID: 11721767
[TBL] [Abstract][Full Text] [Related]
25. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
[TBL] [Abstract][Full Text] [Related]
26. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
[TBL] [Abstract][Full Text] [Related]
27. A comparison of fecal occult-blood tests for colorectal-cancer screening.
Allison JE; Tekawa IS; Ransom LJ; Adrain AL
N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
[TBL] [Abstract][Full Text] [Related]
28. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
[TBL] [Abstract][Full Text] [Related]
29. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
30. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
[TBL] [Abstract][Full Text] [Related]
31. The feasibility of FOBT tests in colorectal cancer screening in Dobrogea.
Suceveanu AI; Suceveanu A; Dumitru E; Alexandrescu L; Voinea F
Rom J Gastroenterol; 2005 Sep; 14(3):213-7. PubMed ID: 16200229
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
Berchi C; Guittet L; Bouvier V; Launoy G
Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780
[TBL] [Abstract][Full Text] [Related]
33. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
Musil D; Tillich J
Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test.
Lejeune C; Dancourt V; Arveux P; Bonithon-Kopp C; Faivre J
Int J Technol Assess Health Care; 2010 Jan; 26(1):40-7. PubMed ID: 20059779
[TBL] [Abstract][Full Text] [Related]
35. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
[TBL] [Abstract][Full Text] [Related]
36. Fecal occult blood testing.
Sanford KW; McPherson RA
Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
[TBL] [Abstract][Full Text] [Related]
37. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
[TBL] [Abstract][Full Text] [Related]
38. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
[TBL] [Abstract][Full Text] [Related]
39. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
[TBL] [Abstract][Full Text] [Related]
40. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
